Dermatology expert Linda Stein Gold, MD, explores the rationale for Janus kinase (JAK) inhibition in atopic dermatitis (AD), clinical trial data on approved and emerging JAK inhibitors in this setting, and the importance of considering JAK inhibitors when creating patient-specific plans for patients with inadequately controlled AD.